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In recent years there has been an increasing interest in
measuring health-related quality of life (HRQoL) with
instruments such as the SF-36. OBJECTIVES: The aim of
this study is to examine the relationship between SF-36
and socio-demographic factors in a general population
sample. We especially focus on differences between men
and women. METHODS: Data was based on a postal
questionnaire sent to a random sample of 8000 inhabit-
ants (response rate 68%) in Uppsala County, Sweden, in
1995. RESULTS: Women reported lower scores than
men on all eight dimensions of SF-36. Physical health
was lower among the older for both men and women.
Mental health was approximately constant with age for
men and slightly higher among older women. Both physi-
cal and mental health were higher among those with
higher education, income and social group. When con-
trolling for the other variables education was not related
to physical and mental health and social group was only
related to physical health. The association of higher men-
tal health scores for those with higher income was stron-
ger for men than for women. Unemployment was associ-
ated with lower mental health, but was not related to
physical health after controlling for the other variables.
The association of unemployment with mental health
was larger for men than for women. Physical health did
not vary with marital status, but for mental health the
scores were lower for persons that are single, divorced or
widows compared to married persons. CONCLUSIONS:
Our results indicate that inequalities in HRQoL are
present with respect to several socioeconomic variables.
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The statistical significance of a phase-III clinical trial will
guide clinical treatment in practice. However, the clinical
trial-based strategy for treatment could be contaminated
by the statistical errors. OBJECTIVES: The study pur-
pose was to formulate the influence of the statistical er-
rors on the cost-effectiveness of the subsequent treatment
strategy based on the result of a phase-III clinical trial.
METHODS: Consider a clinical trial for the two regi-
mens: a new treatment A (TA) and an old treatment B
(TB). Assuming the truth is that TA is more effective than
TB, consider the subsequent three rational scenarios: 1)
no significant difference between TA and TB with the type
II error (), then regard TA and TB as equivalent, 2) prefer
TB to TA with the type III error (), and 3) prefer TA to TB
with the other probability (1--). Then the cost-effec-
tiveness of the scenarios was theoretically evaluated in
use of decision-analytic modeling. RESULTS: Using the
variables  and , the mathematical formula which esti-
mates the cost-effectiveness ratio of the treatment model
was proven to show an intermediate value between the
cost-effectiveness ratios for TA and TB given in the phase-
III clinical trial. If the type II error decreases, the subse-
quent cost-effectiveness ratio approaches to the better
cost-effectiveness ratio given in the phase-III clinical trial.
CONCLUSIONS: It was theoretically proven that ratio-
nal treatment strategy according to the result of a phase-
III clinical trial can improve the cost-effectiveness within
the certain range even if the type II and the type III errors
exist.
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Transforming generic HRQOL instruments to a sum-
mary utility index is useful for deriving quality adjusted
life years (QALY) in any cost/QALY analysis. Neverthe-
less, relatively little research has been done to map or re-
